Skip to main content
TipRanks
Go Ultimate75% OFF

Michael Cruse Insider Profile

4 Followers

Michael Cruse, COO at OnKure Therapeutics, holds 49.45K shares in OnKure Therapeutics (Ticker: OKUR). Most recently, Michael Cruse Bought 7,500 shares of OnKure Therapeutics on Sep 02, 2022 for an estimated value of $25.43K.

Michael Cruse's Trading History

OKUR
OnKure Therapeutics
Sep 02, 2022COOInformative Buy25.43K$130.07K
OKUR
Insider Shares: 49.45K (0.20%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Sep 02, 2022Informative Buy$25.43K7,500$3.39+92.00%
Aug 31, 2022Informative Buy$22.94K7,172$3.19+91.10%
Aug 31, 2022Uninformative Buy$268.9283$3.24―
Dec 14, 2021Uninformative Buy$0.0025,000$0.00―
Aug 26, 2021Informative Buy$18.60K2,500$7.44-47.40%

You May Also Like

Michael Cruse insider profile FAQ

What is the percentage of profitable transactions made by Michael Cruse?
The percentage of profitable transactions made by Michael Cruse is 67%.
What is the average return per transaction made by Michael Cruse?
The average return per transaction made by Michael Cruse is 45.20%.
What stocks does Michael Cruse hold?
Michael Cruse holds: OKUR stocks.
What was Michael Cruse’s latest transaction?
Michael Cruse’s latest transaction was an Informative Buy of $25.43K.
What was Michael Cruse's most profitable transaction?
Michael Cruse’s most profitable transaction was an Informative Buy of OKUR stock on September 2, 2022. The return on the trade was 92.00%.
What is Michael Cruse's role in OnKure Therapeutics?
Michael Cruse's role in OnKure Therapeutics is COO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.